Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis

Table 1

Main characteristics of five studies for diagnosis of tumor included in this meta-analysis.

Number	Study	Country	Year	Numbers of patients; (lesions)	Neoplasm	Sex; (M/F)	Mean age	Imaging	Study design	PET technique	Confirmation
1	Andrei Iagaru	America	2014	8 (30)	Assessable breast cancer lesions	0/8	54.3±8.8	^18F-FPPRGD2 PET/CT	Prospective	329.3MBq; 60min	Histopathology
2	Song Gao	China	2015	26	Assessable lung cancer lesions	15/11	61.62±7.98	^18F-alfatide RGD PET/CT	Prospective	213.34±29.8MBq 60min	Histopathology
3				16 (152)	Assessable lymph nodes	–	–
4	Fei Kang	China	2015	34	Identify NSCLC from lung tuberculosis	19/15	42.4±15.6	^68Ga-Alfatide II RGD PET/CT	Prospective	1.85 MBq/kg 60min	Histopathology
5				17	Assessable lymph nodes	–	–
6	Kun Zheng	China	2015	91	Suspected lung lesions	48/43	56.5 ± 14.9	^68Ga-NOTA-PRGD2 PET/CT	Prospective	111MBq; 30min	Histopathology and follow-up
7				159	Assessable lymph nodes	–	–
8	Yue Zhou	China	2017	13(196)	Assessable lymph nodes	6/7	57±12	^18F-alfatide RGD PET/CT	Prospective	212.15±30.8MBq; 60min	Histopathology
9	Jiang Wu	China	2018	44(53)	Assessable breast cancer lesions	0/44	50.73±8.01	^18F-Alfatide II RGD PET/CT	Prospective	306 ± 80MBq; 60min	Histopathology

M/F: the ratio of male to female.